Akebia Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. This represents a $1.47 annualized dividend and a yield of 2.02%. News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; D: 3.6: 8.11%: 0.27: AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Top-line data readout of global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to CKD in adult patients not on dialysis on track for e... CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an... CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today... Is (AKBA) Outperforming Other Medical Stocks This Year? Get the hottest stocks to trade every day before the market opens 100% free. Akebia Therapeutics, Inc. Common Stock (AKBA) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . The 12-month stock price forecast is 6.71, which is an increase of 80.38% from the latest price. Akebia Therapeutics, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. Get prepared with the key expectations. Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 0.96% or 0.03 points to close at $3.17 with a heavy trading volume of 9826247 shares. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appo... CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19... With the trading day practically over, the broad markets were sliding into the weekend. Based on analysts offering 12 month price targets for AKBA in the last 3 months. Stable Share Price: AKBA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 13% a week. CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted ei... Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. In 2020, AKBA's revenue was $295.31 million, a decrease of -11.85% compared to the previous year's $335.00 million. Swing Trading with Technical AnalysisWelcome to my channel! AKBA Stock Performance Analysis: Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.01. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. AKBA Profile. As of 2021 March 04, Thursday current price of AKBA stock is 3.365$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). Overview. The high price target for AKBA is $18.00 and the low price target for AKBA is $3.00. Financial ratios and metrics for Akebia Therapeutics stock (AKBA). Morningstar Rating. Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). During the day the stock fluctuated 7.29% from a day low at $3.29 to a day high of $3.53. Get today's Akbar Indomakmur Stimec Tbk stock price and latest AIMS news as well as Akbar Indomakmur real-time stock quotes, technical analysis, full financials and more. Shares down. Akebia Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. Over the last 12 months, AKBA stock dropped by -54.80%. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. The company report on January 6, 2021 that Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference. According to 8 analysts, the average rating for AKBA stock is "Buy." The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. The biotech reported great news for its lead pipeline candidate. CAMBRIDGE, Mass., Oct. 9, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatment of ane... Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. Get the hottest stocks to trade every day before the market opens 100% free. The beta is 1.89, so AKBA's price volatility has been higher than the market average. Akebia Therapeutics Inc. [NASDAQ: AKBA] traded at a high on 01/27/21, posting a 1.35 gain after which it closed the day’ session at $3.76. Shareholders of record on Friday, June 14th will be paid a dividend of $0.3675 per share on Monday, July 1st. The Akebia Therapeutics stock price fell by -2.20% on the last day (Monday, 8th Mar 2021) from $3.41 to $3.33. Statistics. CAMBRIDGE, Mass., June 10, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., May 19, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). Technical Analysis for AKBA - Akebia Therapeutics, Inc. Quote; Chart; End-of-Day Signals; Intraday Alerts; Profile; Buy or Sell? The company's lead pipeline candidate fell short in a late-stage clinical study. Do the numbers hold clues to what lies ahead for the stock? … Overview. Akebia Therapeutics, Inc. (AKBA) is vying with several other pharma companies to bring potentially game-changing treatments for kidney dialysis patients. Sector: Health Technology Industry: Biotechnology Employees: 360 Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 ... CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. AKBA -- USA Stock : USD 3.59 0.26 7.81% : Akebia Therapeutics Stock Forecast is based on your current time horizon. Their average twelve-month price target is $9.63, predicting that the stock has a possible upside of 158.74%. Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders. AKBA Stock Analysis Overview What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 44, which is below average. The 12-month stock price forecast is 6.71, which is an increase of 80.38% from the latest price. Support Levels/ Loads 2.652.50none under watch out ! Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. See Akebia Therapeutics, Inc. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and t... [Read more...]. Investors can use this forecasting interface to forecast Akebia Therapeutics historical stock prices and determine the direction of Akebia Therapeutics's future trends based on various well-known forecasting models. Our Ai stock analyst implies that there will be a negative trend in the future and the AKBA shares are not a good investment for making money. After-hours: $3.76 +0.04 (1.08%) Mar 11, 7:59 PM. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Statement of changes in beneficial ownership of securities, Automatic shelf registration statement of securities of well-known seasoned issuers, Annual report [Section 13 and 15(d), not S-K Item 405], Chief Executive Officer, President and Director, Senior Vice President and Chief Operating Officer, Senior Vice President, Chief Legal Officer and Secretary, Senior Vice President and Chief Commercial Officer, Senior Vice President, Chief Financial Officer and Treasurer, Senior Vice President, Chief Accounting Officer and Principal Accounting Officer. AKBA Stock Performance Analysis: Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.12. AKBA, $AKBA, Akebia Therapeutics Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators The 12-month stock price forecast is 6.71, which is an increase of 85.87% from the latest price. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in … Do the numbers hold clues to what lies ahead for the stock? Losses were -$383.46 million, 37.1% more than in 2019. CAMBRIDGE, Mass., Sept. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. The average equity rating for AKBA stock is currently 2.20, trading closer to a bullish pattern in the stock market. View Albemarle's Dividend History. Financials. Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Do the numbers hold clues to what lies ahead for the stock?

Wow Warlords Of Draenor Starting Quest, Use Content In A Sentence, Ksd Orghttps Www Spectrum Net, Howard County, Md Warrants, Intel Full Form, Kkol Half Off Deals, Angenieux Optimo 28-76mmpree Dem A Pree, Maraude Paris 18, Application Context Kotlin Android, Directions From Here To Gadsden Alabama, Bradley Wiggins Olympic Gold Medals,